The angioedema treatment market comprises drugs for the treatment of angioedema such as C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. Angioedema is a sudden localized swelling caused by dilation of blood vessels. It is caused due to the release of vasodilator substances such as bradykinin or other mediators from activated plasma prekallikrein during biochemical reactions involving several plasma protein systems.

The Global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd.

The key opportunities in the angioedema treatment market include rising awareness about hereditary angioedema (HAE), increasing research and development activities for novel therapies, and growing healthcare expenditure.

There is a significant rise in global prevalence of angioedema owing to growing elderly population, increased consumption of drugs inducing angioedema, and modernization leading to adoption of sedentary lifestyle. Major players are focusing on expansion in emerging markets of Asia Pacific and Latin America to tap growth potential.

Market drivers

The primary driver boosting the angioedema treatment market growth is rising global prevalence of angioedema. According to some estimates, hereditary angioedema affects about 1 in 10,000 to 1 in 50,000 people worldwide. Increasing healthcare expenditure in developing nations is also supporting the market growth as it enhances access to diagnosis and treatment of angioedema. Rising research and development activities focused on developing novel drug therapies with better efficacy and tolerability will further fuel the market growth during the forecast period.

PEST Analysis

Political: Drug regulations related to angioedema therapies vary globally and may impact market growth positively or negatively. Regulations regarding drug pricing and reimbursement policies also affect the market.

Economic: Growing healthcare expenditures and increasing per capita incomes are expected to boost demand for angioedema treatments. However, high treatment costs can restrain the market.

Social: Rising angioedema disease prevalence due to risk factors like hereditary angiodema positively impacts the market. Growing awareness about available treatment options augurs well for market players.

Technological: Advances in drug delivery mechanisms help optimize therapy effectiveness. Ongoing R&D focuses on developing novel drug formulations and routes of administration to improve patient outcomes and compliance.

Geographical Regions with High Market Concentration

North America holds the largest market share globally owing to factors like the high disease prevalence, strong reimbursement structure, and availability of advanced treatment options in the region. The US and Canada dominate the North American market.

Fastest Growing Geographical Region

The Asia Pacific region is projected to witness the fastest growth over the forecast period. This can be attributed to increased healthcare spending, growing patients’ pool and rising medical tourism in developing Asian countries such as India and China.